This MinuteCE series examines practical approaches to hyperkalemia management in patients with chronic kidney disease (CKD), heart failure, diabetes, and other cardiorenal comorbidities. Through expert lectures, interviews, and case-based discussions, faculty review guideline-based strategies for managing hyperkalemia while maintaining or optimizing renin-angiotensin-aldosterone system inhibitor (RAASi) and mineralocorticoid receptor antagonist (MRA) therapy. The series compares oral potassium binders by mechanism of action, onset, tolerability, drug-interaction considerations, and sodium- or volume-related concerns. Faculty also address potassium monitoring, recurrent hyperkalemia, and factors that may influence treatment selection, including edema, CKD severity, diabetes, and concomitant therapies. Evidence from DIAMOND and relevant cardiology and nephrology guidelines is incorporated to support informed potassium binder selection and preservation of kidney- and cardiovascular-protective therapy.
The Potassium Shift: Individualizing Hyperkalemia Management With Modern Oral Potassium Binders
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Faculty:
James Burton, DM, FRCP
Professor of Renal Medicine
University of Leicester
Leicester, United Kingdom
Consulting Fees: A. Menarini, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Diaverum
Nihar Desai, MD, MPH
Associate Professor of Medicine
Yale University School of Medicine
New Haven, CT, USA
Consulting Fees: Amgen, CSL Vifor, Merck, Novartis
Contracted Research: Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor
Ellie Kelepouris, MD, FACP, FAHA
Professor of Clinical Medicine
Director of Outpatient Dialysis
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA, USA
Consulting Fees: Bayer, Calliditas, CSL Vifor, Mallinckrodt Pharmaceuticals, Reata, Relypsa, Vera
Royalties: UpToDate
Pauline A. Swift, PhD
Consultant Nephrologist, Renal Services
Epsom and St. Helier University Hospitals NHS Trust
London, United Kingdom
Consulting Fees: Astra Zeneca
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
- Katie Sherida, PhD, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Differentiate oral potassium binders by mechanism of action, efficacy, tolerability, and practical use considerations in patients with chronic kidney disease (CKD), heart failure, and recurrent hyperkalemia
- Apply guideline-based strategies to manage hyperkalemia while optimizing RAASi/MRA therapy
- Individualize the management of hyperkalemia based on heart failure status, edema/volume risk, CKD severity, comorbid diabetes, concomitant medications, and monitoring needs
Target Audience
This activity has been designed to meet the educational needs of nephrologists and cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with hyperkalemia.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-138-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.Commercial Support
TThis activity is supported by an independent educational grant from CSL/VFMCRP.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
